Display options
Cite
Alger BE. Endocannabinoids and their implications for epilepsy. Epilepsy Curr. 2004;4(5):169-73doi: 10.1111/j.1535-7597.2004.04501.x.
Alger, B. E. (2004). Endocannabinoids and their implications for epilepsy. Epilepsy currents, 4(5), 169-73. https://doi.org/10.1111/j.1535-7597.2004.04501.x
Alger, Bradley E. "Endocannabinoids and their implications for epilepsy." Epilepsy currents vol. 4,5 (2004): 169-73. doi: https://doi.org/10.1111/j.1535-7597.2004.04501.x
Alger BE. Endocannabinoids and their implications for epilepsy. Epilepsy Curr. 2004 Sep-Oct;4(5):169-73. doi: 10.1111/j.1535-7597.2004.04501.x. PMID: 16059489; PMCID: PMC1176361.
Copy Download .nbib Format: NLM
Share it on

Epilepsy Curr. 2004 Sep-Oct;4(5):169-73. doi: 10.1111/j.1535-7597.2004.04501.x.

Endocannabinoids and their implications for epilepsy.

Epilepsy currents

Bradley E Alger

Affiliations

  1. Department of Physiology, University of Maryland School of Medicine, Baltimore 21201, USA. [email protected]

PMID: 16059489 PMCID: PMC1176361 DOI: 10.1111/j.1535-7597.2004.04501.x

Abstract

This review covers the main features of a newly discovered intercellular signaling system in which endogenous ligands of the brain's cannabinoid receptors, or endocannabinoids, serve as retrograde messengers that enable a cell to control the strength of its own synaptic inputs. Endocannabinoids are released by bursts of action potentials, including events resembling interictal spikes, and probably by seizures as well. Activation of cannabinoid receptors has been implicated in neuroprotection against excitotoxicity and can help explain the anticonvulsant properties of cannabinoids that have been known since antiquity.

References

  1. J Pharmacol Exp Ther. 2001 Oct;299(1):12-20 - PubMed
  2. J Neurosci. 2003 May 1;23(9):3916-23 - PubMed
  3. J Neurosci. 1992 Oct;12(10):4122-32 - PubMed
  4. Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:619-31 - PubMed
  5. Neuropharmacology. 2002 Sep;43(4):550-62 - PubMed
  6. Science. 2003 Oct 3;302(5642):84-8 - PubMed
  7. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24 - PubMed
  8. Prog Neurobiol. 1999 Jul;58(4):315-48 - PubMed
  9. Neuron. 2001 Aug 16;31(3):453-62 - PubMed
  10. J Neurosci. 2002 Dec 1;22(23):10182-91 - PubMed
  11. J Neurophysiol. 1997 Jul;78(1):43-50 - PubMed
  12. Nat Neurosci. 2002 Aug;5(8):723-4 - PubMed
  13. Br J Pharmacol. 1992 Jun;106(2):231-2 - PubMed
  14. J Pharmacol Exp Ther. 1995 May;273(2):734-43 - PubMed
  15. Science. 2002 Apr 26;296(5568):678-82 - PubMed
  16. Pharmacol Ther. 1997;74(2):129-80 - PubMed
  17. Neuron. 2003 Aug 14;39(4):599-611 - PubMed
  18. Neuroscience. 2003;119(2):481-96 - PubMed
  19. J Neurophysiol. 2000 Mar;83(3):1167-80 - PubMed
  20. Chem Phys Lipids. 2002 Dec 31;121(1-2):3-19 - PubMed
  21. Eur J Neurosci. 2000 Sep;12(9):3239-49 - PubMed
  22. FEBS Lett. 1994 Aug 22;350(2-3):240-4 - PubMed
  23. Prostaglandins Other Lipid Mediat. 2000 Apr;61(1-2):3-18 - PubMed
  24. Neuron. 1991 Apr;6(4):565-74 - PubMed
  25. Science. 1992 Dec 18;258(5090):1946-9 - PubMed
  26. Physiol Rev. 2003 Jul;83(3):1017-66 - PubMed
  27. Neuron. 2001 Mar;29(3):729-38 - PubMed
  28. Nat Rev Neurosci. 2003 Nov;4(11):873-84 - PubMed
  29. Philos Trans R Soc Lond B Biol Sci. 2001 Mar 29;356(1407):381-408 - PubMed
  30. Nature. 2001 Mar 29;410(6828):588-92 - PubMed
  31. Nat Neurosci. 1999 Apr;2(4):358-63 - PubMed
  32. Life Sci. 1999;65(6-7):573-95 - PubMed
  33. Neuron. 2001 Mar;29(3):717-27 - PubMed
  34. Neuron. 2003 May 8;38(3):461-72 - PubMed
  35. Nature. 1998 Jul 16;394(6690):277-81 - PubMed
  36. Nature. 2001 Apr 12;410(6830):822-5 - PubMed
  37. J Neurosci. 2000 Apr 1;20(7):2470-9 - PubMed
  38. Nature. 2002 Aug 1;418(6897):530-4 - PubMed
  39. Neuron. 2001 Aug 16;31(3):463-75 - PubMed
  40. J Pharmacol Exp Ther. 2001 Jul;298(1):7-14 - PubMed
  41. Nature. 1990 Aug 9;346(6284):561-4 - PubMed
  42. J Neurosci. 2001 Dec 15;21(24):RC188 - PubMed
  43. Prog Neurobiol. 2002 Nov;68(4):247-86 - PubMed

Publication Types